Dr. Mahon is a professor in the departments of Medicine and Epidemiology and Biostatistics at the University of Western Ontario (Western). He is the director of Clinical Safety, Robarts Clinical Trials, at the Robarts Research Institute. He graduated in medicine from the University of Alberta and trained in internal medicine and endocrinology at Memorial University of Newfoundland and Western, where he also received his masters in epidemiology and biostatistics. He has a clinical practice in adult endocrinology with a focus on type 1 diabetes, and has helped develop Evidence-Based Clinical Practice Guidelines for persons with diabetes in Canada since 1998.
Dr. Mahon is participating in clinical studies looking for ways to predict and prevent type 1 diabetes mellitus - a serious disease that is usually caused by an immune response that destroys the insulin-producing (or beta-) cells of the pancreas. The majority of beta-cells are lost before the person develops symptomatic hyperglycemia. This subclinical phase is probably provoked by an environmental trigger or triggers in genetically at-risk persons and can be detected by blood tests other than glucose levels including beta-cell autoantibodies. This has made it possible to predict future type 1 diabetes, and to also test treatments that control beta-cell loss in at-risk persons. Because existing prediction tests could be better, Dr. Mahon and other members of the TrialNet-Type 1 Diabetes Study Group are assessing whether other tests more accurately predict future type 1 diabetes (The TrialNet Natural History Study of Type 1 Diabetes). As part of the TrialNet and TRIGR (Trial to Reduce Insulin-dependent-diabetes in the Genetically at-Risk) Study Groups, Dr. Mahon is also participating in randomized trials of type 1 diabetes preventions.